Logo image
Stereotactic Radiosurgery for Trigeminal Schwannomas: A 28-Year Single-Center Experience and Review of the Literature
Journal article   Peer reviewed

Stereotactic Radiosurgery for Trigeminal Schwannomas: A 28-Year Single-Center Experience and Review of the Literature

M. Harrison Snyder, Matthew J. Shepard, Ching-Jen Chen and Jason P. Sheehan
World Neurosurgery, Vol.119
2018

Abstract

Adult Aged Aged, 80 and over Cranial Nerve Neoplasms Female Humans Male Middle Aged Neurilemmoma Radiosurgery Radiotherapy Dosage Retrospective Studies Treatment Outcome Trigeminal Nerve Diseases Tumor Burden gadolinium adult aged Article cancer control clinical article cranial neuropathy deterioration facial paresthesia female follow up gamma knife radiosurgery headache human male neurilemoma neurofibromatosis type 2 neuroimaging nuclear magnetic resonance imaging oncological parameters outcome assessment paresthesia postoperative complication radiation injury radiation response retrospective study stereotactic radiosurgery trigeminal schwannoma trigeminus neuralgia tumor growth tumor regression tumor volume very elderly x-ray computed tomography cranial nerve tumor middle aged neurilemoma pathology procedures radiosurgery radiotherapy dosage treatment outcome trigeminal nerve disease
Objective: To assess outcomes and complications of stereotactic radiosurgery treatment for trigeminal schwannoma (TS). Methods: A retrospective analysis was performed to describe the presentation and outcomes of patients undergoing Gamma Knife radiosurgery (GKRS) for TS. Clinical, radiographic, and stereotactic radiosurgery dose plans were reviewed. Descriptive statistics and univariate analysis were performed to identify factors associated with poor tumor control. Results: A total of 22 patients with TS were treated with GKRS between 1990 and 2018. One patient had a history of neurofibromatosis type II. Of the study population, 81% underwent GKRS as a first-line treatment. The average tumor volume was 3.3 cm3 and the average margin treatment dose was 14.1 Gy. The median clinical and radiographic follow-up period were 18.5 and 27 months, respectively. Tumor control was achieved in 17 patients (77.3%). Symptomatic improvement was noted in 8 patients (42.1%). Tumor expansion was observed in 7 patients (31.8%) and was associated with poor tumor control at last follow-up (P < 0.05). Patients who developed transient tumor expansion had higher margin doses (14.9 ± 1.1 Gy) compared with patients who did not have expansion (13.6 ± 1.3 Gyk P < 0.05). Conclusions: GKRS provides effective control for most TS. Increased margin doses are associated with tumor expansion, which was a poor prognostic event associated with progression and clinical decline. Based on these results, combined with analysis of available data from other series of TS treated with GKRS, we believe that margin dose between 13 and 14 Gy offers a high probability of tumor control, yet minimizing risk of adverse radiation effects. © 2018 Elsevier Inc.

Metrics

15 Record Views

Details

Logo image